Algeta appoints Dr. Donald Coppen as Business Development Director
Algeta ASA announced that it has appointed Donald Coppen as business development Director.
Dr. Coppen will join Chief Business Officer Roger Harrison in driving Algeta's business development strategy aimed at advancing its Thorium payload technology for creating novel targeted cancer therapies, and expanding the Company's pipeline of product candidates.
Dr. Coppen joins Algeta from Biocompatibles International (now part of BTG plc), a UK-based oncology company developing drug-device combination products, where he was Director, Partnering & Licensing. He has previously held project leadership and managerial roles at Lonza Biologics in the UK, and within the crop protection division of Cyanamid International, part of Wyeth (now Pfizer), in Belgium.
Dr. Coppen has a PhD from the University of Southampton and a MBA from the Cranfield School of Management.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.